Trial Profile
Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 May 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.